Literature DB >> 11277595

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.

E Arnáiz1, V Jelic, O Almkvist, L O Wahlund, B Winblad, S Valind, A Nordberg.   

Abstract

The objective of this study was to assess whether reduced glucose metabolism (rCMRGlu) and cognitive functioning could predict development of Alzheimer's disease (AD) in subjects with mild cognitive impairment (MCI). Twenty MCI patients underwent baseline and follow-up investigations of rCMRGlu, as measured by PET, and cognitive function measured by neuropsychological test assessments. Subjects were clinically followed up with an average interval of 36.5 months. Two groups were obtained after the second clinical assessment. Nine patients were diagnosed as AD and classified as progressive MCI (P-MCI), whereas 11 patients remained clinically stable and were classified as stable MCI (S-MCI). There were no differences in demographic variables or baseline MMSE between the two subgroups. Logistic regression indicated the two variables that most effectively predicted future development of AD were rCMRGlu from the left temporoparietal area and performance on the block design. These combined measures gave an optimal 90% correct classification rate, whereas only rCMRGlu or neuropsychology alone gave 75% and 65% correct classification, respectively. Measures of temporoparietal cerebral metabolism and visuospatial function may aid in predicting the evolution to AD for patients with MCI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277595     DOI: 10.1097/00001756-200103260-00045

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  65 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

Authors:  José V Pardo; Joel T Lee; Michael A Kuskowski; Kristin R Munch; John V Carlis; Sohail A Sheikh; Christa Surerus; Scott M Lewis; J Riley McCarten; Howard Fink; Susan McPherson; Hemant H Shah; Susan Rottunda; Maurice W Dysken
Journal:  Alzheimers Dement       Date:  2010-05-06       Impact factor: 21.566

3.  Brain metabolic correlates of decision making in amnestic mild cognitive impairment.

Authors:  H Randall Griffith; Ozioma C Okonkwo; Jan A den Hollander; Katherine Belue; Jacqueline Copeland; Lindy E Harrell; John C Brockington; David G Clark; Daniel C Marson
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2010-04-06

4.  Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study.

Authors:  Nabil Maalikjy Akkawi; B Borroni; C Agosti; M Magoni; M Broli; A Pezzini; A Padovani
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

Review 5.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

6.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

7.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Authors:  Lisa Mosconi; Wai H Tsui; Henry Rusinek; Susan De Santi; Yi Li; Gene-Jack Wang; Alberto Pupi; Joanna Fowler; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.